Chi-Med to Announce 2020 Final Results

Rhea-AI Summary

Hutchison China MediTech Limited (HCM) will announce its final results for the fiscal year ending December 31, 2020, on March 4, 2021. The announcement will take place at 12:00 noon GMT, with a conference call and audio webcast scheduled for 1:00 pm GMT. Chi-Med is a biopharmaceutical company focused on the development of targeted therapies and immunotherapies for cancer and immunological diseases, boasting a portfolio of nine clinical drug candidates and a strong presence in China.

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Standard Time (EST).

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management.

The conference call and audio webcast will take place at 1:00 pm GMT / 9:00 pm HKT / 8:00 am EST on Thursday, March 4, 2021 and will be webcast live via the company website at www.chi-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President	+852 2121 8200
Annie Cheng, Vice President	+1 (973) 567 3786
Media Enquiries
Americas – Brad Miles, Solebury Trout	+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com
Europe – Ben Atwell / Alex Shaw, FTI Consulting	+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Chi-Med@fticonsulting.com
Asia – Joseph Chi Lo / Zhou Yi, Brunswick	+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited	+44 (20) 7886 2500

 

FAQ

When will Hutchison China MediTech announce its financial results for 2020?

Hutchison China MediTech will announce its financial results for the year ended December 31, 2020, on March 4, 2021.

What time is the conference call for Hutchison China MediTech's financial results?

The conference call will be held at 1:00 pm GMT on March 4, 2021.

How can I access the audio webcast for Hutchison China MediTech's financial results?

The audio webcast can be accessed live via the company's website at www.chi-med.com.

What does Hutchison China MediTech focus on?

Hutchison China MediTech focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases.

How many clinical drug candidates does Hutchison China MediTech have?

Hutchison China MediTech has a portfolio of nine cancer drug candidates currently in clinical studies.